TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37209243

Group type: EXPERIMENTAL
Intervention: Intraosseous computerized anaesthesia (ICA) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB) with 1.8 mL of 4% articaine with 1:100 000 epinephrine
Number of subjects: 72
Study: 37209422

Group type: EXPERIMENTAL
Intervention: Technology-based training in exposure therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Integrated behavioral health setting
Number of subjects: 13
Study: 37209421

Group type: EXPERIMENTAL
Intervention: Enhanced treatment support via free combination NRT at discharge and automated counseling
Number of subjects: 321

Group type: COMPARATOR
Intervention: Usual care (quitline-based approach)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Enhanced treatment support
Number of subjects: 321
Study: 37209427

Group type: EXPERIMENTAL
Intervention: Ulotaront 25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ulotaront 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 37209700

Group type: EXPERIMENTAL
Intervention: AAd5 (0.1 mL)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: IMAd5 (0.3 mL)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Inactivated vaccine (BBIBP-CorV or CoronaVac; 0.5 mL)
Number of subjects: 360
Study: 37209779

Group type: EXPERIMENTAL
Intervention: Modernized collaborative care for depression
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard care for depression
Number of subjects: 216
Study: 37209893

Group type: EXPERIMENTAL
Intervention: Intrauterine balloon tamponade combined with sulprostone infusion
Number of subjects: 403

Group type: COMPARATOR
Intervention: Intrauterine balloon tamponade after sulprostone infusion
Number of subjects: 403
Study: 37209934

Group type: EXPERIMENTAL
Intervention: miWe wheelchair simulator (simulator group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: kart driving videogame (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 37209996

Group type: EXPERIMENTAL
Intervention: Drug Coated Balloons (DCBs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Balloons
Number of subjects: 40
Study: 37210041

Group type: EXPERIMENTAL
Intervention: Pregnancies with optimal anti-infective prophylaxis
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pregnancies in women with PID
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: History of severe infection
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes in women with PID
Number of subjects: 93
Study: 37210048

Group type: EXPERIMENTAL
Intervention: 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART), 50 gray in 5 fractions.
Number of subjects: 136
Study: 37210075

Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT program with advance notification 'primers' (live calls and texts) and automated reminders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Live phone primers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Advance notifications sent by text
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT program
Number of subjects: 70
Study: 37210072

Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC) combined with energy restriction recommendations (ROC+)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 129
Study: 37210098

Group type: EXPERIMENTAL
Intervention: 75 mg rimegepant
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study: 37210099

Group type: EXPERIMENTAL
Intervention: Valbenazine (≤80 mg, as tolerated)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Valbenazine
Number of subjects: 128
Study: 37210220

Group type: EXPERIMENTAL
Intervention: RV-PA coupling (TAPSE/PASP ratio <0.39)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: RV-PA uncoupling (TAPSE/PASP ratio >0.39)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: RV-PA coupling
Number of subjects: 404

Group type: COMPARATOR
Intervention: No RVD
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: RV-PA uncoupling after TAVI
Number of subjects: 404
Study: 37210308

Group type: EXPERIMENTAL
Intervention: mRNA-1388 25 μg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA-1388 50 μg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA-1388 100 μg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA-1388 (all doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mRNA-1388 (50 μg and 100 μg)
Number of subjects: 60
Study: 37210516

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 254
Study: 37210543

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 162
Study: 37210608

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1209
Study: 37210665

Group type: EXPERIMENTAL
Intervention: Communication-priming intervention (Jumpstart Guide)
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Communication-priming intervention (Jumpstart Guide) among patients with minoritized race or ethnicity
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Usual care among patients with minoritized race or ethnicity
Number of subjects: 2512

Group type: EXPERIMENTAL
Intervention: Communication-priming intervention (Jumpstart Guide) among non-Hispanic White patients
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Usual care among non-Hispanic White patients
Number of subjects: 2512
Study: 37210741

Group type: EXPERIMENTAL
Intervention: 1 dose of 5-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 doses of 5-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 doses of 25-µg rS with 50 µg Matrix-M adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37210742

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Metolazone 5-10 mg once daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Metolazone
Number of subjects: 61
Study: 37210887

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy plus a Memory Support Intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cognitive Therapy as usual
Number of subjects: 178
Study: 37211138

Group type: EXPERIMENTAL
Intervention: Microperimetry-derived perilesional sensitivity
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low-vision Cambridge Color Test
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Full-field electroretinography (ERG)
Number of subjects: 67
Study: 37211143

Group type: EXPERIMENTAL
Intervention: Elective repair
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Truly untreated status
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ruptures among truly untreated women
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mortality among truly untreated women
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reasons for nonintervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Eligibility for endovascular repair
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 55-mm threshold analysis
Number of subjects: 200
Study: 37211146

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 0
Study: 37211155

Group type: EXPERIMENTAL
Intervention: Buprenorphine access in Massachusetts Wave 2 HCS communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2SFCA index scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid-related incidents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rural communities' access to buprenorphine prescribers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suburban communities' opioid-related incidents
Number of subjects: 0
Study: 37211246

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg and 30 mg
Number of subjects: 36
Study: 37211338

Group type: EXPERIMENTAL
Intervention: Screening positive for glaucoma or suspected glaucoma
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Identifying as Black/African-American
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Having an established eyecare clinician
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Not driving a personal vehicle to the appointment
Number of subjects: 1171

Group type: COMPARATOR
Intervention: ADI comparison
Number of subjects: 1171

Group type: COMPARATOR
Intervention: White participants at FQHC vs. free clinic
Number of subjects: 1171

Group type: COMPARATOR
Intervention: ADI comparison for White participants
Number of subjects: 1171
Study: 37211611

Group type: EXPERIMENTAL
Intervention: Home-based multicomponent exercise program with weekly telephone supervision from diagnosis until three months post-surgery
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 250
Study: 37211764

Group type: EXPERIMENTAL
Intervention: Closed suction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open suction
Number of subjects: 20
Study: 37211798

Group type: EXPERIMENTAL
Intervention: Educational intervention for family nursing students
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 69
Study: 37211832

Group type: EXPERIMENTAL
Intervention: Foster care (N=68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Care as usual (N=68)
Number of subjects: 136
Study: 37211883

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions during cord blood transplant (CBT)
Number of subjects: 10
Study: 37211950

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 162
Study: 37211963

Group type: EXPERIMENTAL
Intervention: PSMA-targeted intervention
Number of subjects: 22
Study: 37211967

Group type: EXPERIMENTAL
Intervention: Cardiovascular gain-framed letter
Number of subjects: 65075

Group type: EXPERIMENTAL
Intervention: Repeated letter at day 14
Number of subjects: 65075

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65075
Study: 37211977

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11007
Study: 37212068

Group type: EXPERIMENTAL
Intervention: Early Non-Invasive Ventilation (NIV) initiation (FVC below 75%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Non-Invasive Ventilation (NIV) initiation (FVC below 50%)
Number of subjects: 42
Study: 37212116

Group type: EXPERIMENTAL
Intervention: GrimAge clock markers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DNAmTL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neuropsychiatric Inventory severity scores
Number of subjects: 45
Study: 37212168

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 37212312

Group type: EXPERIMENTAL
Intervention: High-risk sexual contacts of mpox patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-risk nonsexual contacts of mpox patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Presymptomatic phase of infection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sexual contacts of mpox cases
Number of subjects: 25
Study: 37212315

Group type: EXPERIMENTAL
Intervention: AVT04 (ustekinumab candidate biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product (RP) ustekinumab (EU-approved and US-licensed Stelara®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three treatment arms (AVT04, US-RP, EU-RP)
Number of subjects: 0
Study: 37212440

Group type: EXPERIMENTAL
Intervention: NI006
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37212442

Group type: EXPERIMENTAL
Intervention: Dual-chamber leadless pacemaker system
Number of subjects: 300
Study: 37212600

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2859

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2859
Study: 37212651

Group type: EXPERIMENTAL
Intervention: Sertraline (25-100 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 184
Study: 37212686

Group type: EXPERIMENTAL
Intervention: Sintilimab plus S-1 combined intraperitoneal and intravenous paclitaxel
Number of subjects: 36
Study: 37212760

Group type: EXPERIMENTAL
Intervention: Guideline intervention
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Treatment fee item intervention
Number of subjects: 504
Study: 37212796

Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan (HER3-DXd)
Number of subjects: 0
Study: 37212825

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine-gynx
Number of subjects: 104
Study: 37212970

Group type: EXPERIMENTAL
Intervention: Heavy lifting strength training (HLST) program, 12 weeks, twice weekly, lifting 80-90% of 1 repetition maximum (1RM)
Number of subjects: 9
Study: 37213005

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 837
Study: 37213030

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 37213048

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 10×1-min intervals ≥90% maximum heart rate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 15
Study: 37213102

Group type: EXPERIMENTAL
Intervention: Danuglipron 120 mg twice daily
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Danuglipron 80 mg twice daily
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 37213109

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 5047
Study: 37213122

Group type: EXPERIMENTAL
Intervention: Dual thrombolytic treatment with 5 mg intravenous alteplase and 40 mg intravenous mutant prourokinase
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care with 0.9 mg/kg intravenous alteplase
Number of subjects: 238
Study: 37213187

Group type: EXPERIMENTAL
Intervention: ACT program (intervention) includes predischarge kidney health education from nurses and coordinated postdischarge laboratory monitoring (serum creatinine and urine protein assessment) and follow-up with a primary care provider and pharmacist within 14 days.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (control) receives no specific study-related intervention, with AKI care at the direction of the treating team.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ACT program (intervention)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 34
Study: 37213195

Group type: EXPERIMENTAL
Intervention: Personalized content in a tailored style (PT) + usual care (UC)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Personalized content in a nontailored style (PN) + usual care (UC)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Personalized content in a tailored style (PT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Personalized content in a nontailored style (PN)
Number of subjects: 169
Study: 37213481

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) at 150 to 200 kHz
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields)
Number of subjects: 4
Study: 37213661

Group type: EXPERIMENTAL
Intervention: Subchondroplasty (SCP)
Number of subjects: 50
Study: 37213724

Group type: EXPERIMENTAL
Intervention: Pre-visit educational video and pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamphlet alone
Number of subjects: 0
Study: 37213900

Group type: EXPERIMENTAL
Intervention: Cortical superficial siderosis (cSS) present
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Large hematoma volume
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: cSS
Number of subjects: 673
Study: 37213907

Group type: EXPERIMENTAL
Intervention: Electromagnetic Network Targeting Field (ENTF) therapy
Number of subjects: 344

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 344
Study: 37213913

Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 25
Study: 37214171

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37214210

Group type: EXPERIMENTAL
Intervention: MALT1 inhibitor
Number of subjects: 0
Study: 37214431

Group type: EXPERIMENTAL
Intervention: Exogenous DL-beta-hydroxybutyrate supplementation, dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0
Study: 37214450

Group type: EXPERIMENTAL
Intervention: vonoprazan-containing triple therapy
Number of subjects: 0
Study: 37214806

Group type: EXPERIMENTAL
Intervention: Pediatric Observational Cohort Study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data and biosamples collection
Number of subjects: 0
Study: 37214840

Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 37214890

Group type: EXPERIMENTAL
Intervention: Strengths-based and community-driven intervention to reduce gun violence, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0
Study: 37214968

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study: 37215108

Group type: EXPERIMENTAL
Intervention: TCR T cells overexpressing c-Jun
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-A2/AFP TCR
Number of subjects: 0
Study: 37215110

Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 37215141

Group type: EXPERIMENTAL
Intervention: Exome sequencing (ES)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Chromosomal microarray analysis (CMA)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Combined approach of ES and CMA
Number of subjects: 332
Study: 37215348

Group type: EXPERIMENTAL
Intervention: VACStent
Number of subjects: 50
Study: 37215389

Group type: EXPERIMENTAL
Intervention: Low-dose prucalopride (0.04 mg/kg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High-dose prucalopride (0.08 mg/kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 37215391

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT)
Number of subjects: 40
Study: 37215551

Group type: EXPERIMENTAL
Intervention: Therapeutic concordance approach
Number of subjects: 282
Study: 37215644

Group type: EXPERIMENTAL
Intervention: Community gardening (receiving a community garden plot, plants and seeds, and a gardening class)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waitlist for a community garden plot)
Number of subjects: 0
Study: 37215679

Group type: EXPERIMENTAL
Intervention: Non-Violent Resistance (NVR) program, a 10-session parental-group intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual (TAU), supportive counseling and psychoeducation
Number of subjects: 82
Study: 37215725

Group type: EXPERIMENTAL
Intervention: EDP1815
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37215727

Group type: EXPERIMENTAL
Intervention: Presepsin:gelsolin (PSEP:GSN) ratio
Number of subjects: 126

Group type: COMPARATOR
Intervention: Routine lab and clinical parameters
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: PSEP:GSN ratio
Number of subjects: 126
Study: 37216212

Group type: EXPERIMENTAL
Intervention: Autologous tissue reconstruction (ATR, n = 127)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Implant-based reconstruction (IBR, n = 60)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Combined autologous tissue and implant reconstruction (n = 60)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Immediate reconstruction (IR)
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 1651
Study: 37216230

Group type: EXPERIMENTAL
Intervention: MTCN+ model
Number of subjects: 363

Group type: COMPARATOR
Intervention: MTCN model
Number of subjects: 363

Group type: COMPARATOR
Intervention: Artificial model
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: MTCN+ model in small primary tumors
Number of subjects: 363
Study: 37216357

Group type: EXPERIMENTAL
Intervention: Short-term antibiotic treatment (8 weeks in early IOM and 12 weeks in delayed IOM)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Long-term antibiotic treatment (12 weeks in early IOM or until fracture healing or implant removal in delayed IOM)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Both short-term and long-term treatments
Number of subjects: 364
Study: 37216396

Group type: EXPERIMENTAL
Intervention: Vemurafenib (20 mg/kg) combined with Ara-C (100 mg/m2 every 12 h, days 1-5) and 2-CdA (6 mg/m2 per day, days 1-5) followed by mono 2-CdA.
Number of subjects: 19
Study: 37216921

Group type: EXPERIMENTAL
Intervention: Crinecerfont (50 mg twice daily for 14 days)
Number of subjects: 8